electroCore, Inc. (ECOR) News & EventsECORelectroCore, Inc.

electroCore Reports Q2 Revenue of $8.18M, Below Consensus

Reports Q2 revenue $8.18M, consensus $9.49M. "This quarter marked a new era for our company as we implemented significant changes across our commercial organization to better position us for long-term success," said Joshua Lev, Interim President and Chief Financial Officer of electroCore. "While these actions required investment and focus throughout the quarter, we believe they have strengthened our foundation, improved operating efficiency, and enhanced our ability to accelerate revenue growth. We are encouraged by the early results, and we believe these changes will help us drive sustainable top-line growth and achieve positive Adjusted EBITDA in the third quarter of 2027."

Company Raises 2026 Revenue Guidance to Over 30% Growth

The company said, "The Company is raising its full-year 2026 revenue guidance to greater than 30% annual growth over full-year 2025 and expects to achieve positive Adjusted EBITDA in the third quarter of 2027."

electroCore Quell Device Clinical Trial Shows Significant Improvement in Fibromyalgia Patients

electroCore published clinical findings in JAMA Network Open from a cluster randomized trial evaluating its Quell device added to outpatient physical therapy, or PT, in 384 fibromyalgia patients. At day 60, reduction in movement-evoked pain was significantly greater in the PT-Quell group compared with the PT-only group, with statistically significant improvements also seen in resting pain, pain interference, movement-evoked fatigue, resting fatigue, and fibromyalgia impact. Benefits were observed within 30 days and sustained for up to six months, with 81% of respondents finding Quell helpful and 55% continuing daily use.